{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:02:54Z","timestamp":1791525774470,"version":"4.3.4"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy caused by the autoantibody of aquaporin-4 (AQP4). Herein, we report a case of Tolosa-Hunt syndrome presenting with abducens palsy and AQP4 antibodies. This was a rare case of AQP4-immunoglobulin G seropositivity in a patient with Tolosa-Hunt syndrome. Our findings may expand the clinical phenotype of NMOSD and indicate that clinicians should consider testing for AQP4 antibodies in patients with Tolosa-Hunt syndrome.<\/jats:p>","DOI":"10.3389\/fneur.2024.1326867","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T04:39:55Z","timestamp":1707885595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Tolosa-Hunt syndrome\u2014expanding the neuromyelitis optica spectrum disorder phenotype?"],"prefix":"10.3389","volume":"15","author":[{"given":"Soo-Hyun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Im","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ja","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO Spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"205521732110526","DOI":"10.1177\/20552173211052656","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"Redenbaugh","year":"2021","journal-title":"Mult Scler J Exp Transl Clin Oct"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica study group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/cen3.12542","article-title":"Probable neuromyelitis optica spectrum disorder presenting with recurrent cranial neuropathy","volume":"10","author":"Tateno","year":"2019","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100885","DOI":"10.1016\/j.preteyeres.2020.100885","article-title":"Non-specific orbital inflammation: current understanding and unmet needs","volume":"81","author":"Lee","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jnnp.71.5.577","article-title":"The Tolosa-hunt syndrome","volume":"71","author":"Kline","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10072-015-2124-2","article-title":"The evaluation of ICHD-3 beta diagnostic criteria for Tolosa-hunt syndrome: a study of 22 cases of Tolosa-hunt syndrome","volume":"36","author":"Hao","year":"2015","journal-title":"Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/practneurol-2018-001951","article-title":"Time to retire the Tolosa-hunt syndrome?","volume":"18","author":"Lueck","year":"2018","journal-title":"Pract Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1177\/1352458519895444","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated diffuse orbital inflammation","volume":"26","author":"Deschamps","year":"2020","journal-title":"Mult Scler"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/WNO.0000000000001400","article-title":"Orbital inflammation in myelin oligodendrocyte glycoprotein antibody-associated disease: a case report and review of the literature","volume":"42","author":"Liou","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-510X(97)00205-0","article-title":"Recurrent cranial neuropathy as a clinical presentation of idiopathic inflammation of the dura mater: a possible relationship to Tolosa-hunt syndrome and cranial pachymeningitis","volume":"154","author":"Miwa","year":"1998","journal-title":"J Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1111\/ene.13453","article-title":"Meningeal and vestibulocochlear nerve enhancement in neuromyelitis optica","volume":"24","author":"Bonnan","year":"2017","journal-title":"Eur J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jneuroim.2015.08.001","article-title":"Hypertrophic pachymeningitis accompanying neuromyelitis optica spectrum disorder: a case report","volume":"287","author":"Kon","year":"2015","journal-title":"J Neuroimmunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1111\/j.1468-1331.2012.03667.x","article-title":"Cortical and leptomeningeal involvement in three cases of neuromyelitis optica","volume":"19","author":"Tahara","year":"2012","journal-title":"Eur J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1016\/j.jocn.2014.04.019","article-title":"Audiological evidence of therapeutic effect of steroid treatment in neuromyelitis optica with hearing loss","volume":"21","author":"Takanashi","year":"2014","journal-title":"J Clin Neurosci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1326867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T04:39:59Z","timestamp":1707885599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1326867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":17,"alternative-id":["10.3389\/fneur.2024.1326867"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1326867","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"article-number":"1326867"}}